PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of Castration Resistant Prostate Cancer (CRPC) Patients Treated with Abiraterone Acetate

Request Access

A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate–prednisone

Liang Wang, Liang Wang, S. Dehm, et al.. (2018). Annals of Oncology. Cited 83 times. https://doi.org/10.1093/annonc/mdx689

Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer

S. Hart, Marissa S. Ellingson, Kimberly A. Schahl, et al.. (2016). BMJ Open. Cited 38 times. https://doi.org/10.1136/bmjopen-2015-010332

Mutational Landscapes of Sequential Prostate Metastases and Matched Patient Derived Xenografts during Enzalutamide Therapy

M. Kohli, Liguo Wang, Fang Xie, et al.. (2015). PLoS ONE. Cited 29 times. https://doi.org/10.1371/journal.pone.0145176

A Prospective Correlation of Tissue Histopathology With Nucleic Acid Yield in Metastatic Castration-Resistant Prostate Cancer Biopsy Specimens

R. Jimenez, T. Atwell, Hughes Sicotte, et al.. (2019). Mayo Clinic Proceedings: Innovations, Quality & Outcomes. Cited 11 times. https://doi.org/10.1016/j.mayocpiqo.2018.12.005
NCPI Dataset Catalog
Feedback & Support
v0.9.0-d9e5747